Breast Cancer and Osteoporosis: What Is the Relationship?

Some cancer treatments increase osteoporosis risk

Table of Contents
View All
Table of Contents

Breast cancer and osteoporosis are both relatively common health conditions in women, whose risk for both conditions increases as they age. Many breast cancer treatments contribute to the development of osteoporosis, affecting bone health and potentially leading to serious fractures. 

This article discusses the connection between breast cancer and osteoporosis, associated risks, and ways to decrease them.

Senior woman with cancer

FatCamera / Getty Images

Connections Between Breast Cancer and Osteoporosis

Because both breast cancer and osteoporosis are common in postmenopausal women, it’s not surprising that many women who have had breast cancer also develop osteoporosis.

However, women who have had breast cancer are at a greater risk of osteoporosis than women who haven't had breast cancer. Scientists believe this is due to the way some breast cancer treatments affect and weaken the bones.  

Bone Loss From Cancer Treatment

It’s estimated that up to 80% of breast cancer patients experience some degree of bone loss due to their treatment history.

Women with breast cancer also seem to have a higher risk of fractures than women without breast cancer and an increased risk for more severe osteoporosis.

Unfortunately, many women with breast cancer don’t know that they have an increased risk of osteoporosis and don’t realize there are ways to help prevent it.


Breast cancer generally increases the risk of osteoporosis, but women with estrogen receptor-positive breast cancer have an even greater risk of developing osteoporosis. This is likely due to the cancer treatments required for this disease.

Risks From Aromatase Inhibitors

Aromatase inhibitor drugs, such as Femara (letrozole) and Arimidex (anastrozole), are standard treatments for most postmenopausal women with estrogen receptor-positive breast cancer. These drugs lower the active estrogen in the body, which helps treat cancer. 

But the cells inside your bones also have estrogen receptors to help maintain bone mass. Taking aromatase inhibitors blocks estrogen signaling in your bones, which can increase your risk of osteoporosis. These drugs can be taken for years to help treat breast cancer or prevent recurrence and can significantly impact bone health over time.

Risks From Other Breast Cancer Therapies

Other breast cancer treatments that may increase the risk of osteoporosis include:

The risks of some breast cancer therapies are unclear. For example, Soltamox (tamoxifen) may decrease the risk of osteoporosis when taken after menopause but increase it when taken before.

Treatment and Management of Breast Cancer With Osteoporosis

Treating and managing breast cancer and osteoporosis will depend on your breast cancer type, the severity of breast cancer and/or osteoporosis, your age, other medical issues and risk factors you may have, and personal preferences. 

Some women have preexisting osteoporosis before starting treatment, while others may have issues with bone health during or after it's complete. Breast cancer treatment takes priority over osteoporosis treatment, even if it slightly increases your risk of osteoporosis later. 

However, speak to your healthcare provider early to determine the best breast cancer treatment for you.


Lifestyle changes, medication, and preventive bone scans can all help prevent osteoporosis.

Lifestyle Changes

Although certain risk factors for osteoporosis cannot be changed, like age, sex, or history of breast cancer treatment, you can make lifestyle choices to help decrease your risk. Quitting smoking, drinking moderately (or abstaining), and getting enough exercise can help.

Getting enough calcium and vitamin D to help maximize your bone strength is also essential. Your healthcare provider can help you determine levels and suggest supplements or dietary changes if you aren't getting enough of these nutrients.

DEXA Scan for Bone Density

The American Cancer Society recommends that all postmenopausal breast cancer survivors get a DEXA scan, which measures bone density. The following groups of women with breast cancer should also get scans every two years:

  • Women taking aromatase inhibitors
  • Premenopausal women taking tamoxifen or a GnRH agonist
  • Women who went through menopause prematurely due to chemotherapy

In general, the National Osteoporosis Foundation recommends bone mineral density testing in women 65 and older and in women 50 years or older with multiple risk factors for osteoporosis, such as breast cancer.


Some women benefit from medications to help build bone strength and prevent osteoporotic fractures and may be a good option if you have a moderate or high fracture risk.

Several of these medications include:

  • Oral bisphosphonates, such as Fosamax (alendronate) or Actonel (risedronate) 
  • Bisphosphonates taken through your veins, like Reclast (zoledronic acid)
  • Forteo (teriparatide)
  • Tymlos (abaloparatide)
  • Prolia (denosumab)
  • Evenity (romosozumab)

Another option may be selective estrogen receptor modulators (SERMs). This group of drugs, including Evista (raloxifene), is sometimes prescribed to help prevent osteoporosis. However, these drugs may also help prevent breast cancer for those with higher risk. It's unclear of their benefit, however, if you've already had breast cancer.

Some evidence also suggests that bisphosphonate drugs given for osteoporosis might also help prevent cancer recurrence in the bone, at least in postmenopausal women at the start of treatment.


Osteoporosis and breast cancer are relatively common conditions in women, especially after menopause. Many women will experience both health issues just by chance. However, getting breast cancer increases your risk of osteoporosis and of breaking a bone, likely due to the effects of breast cancer treatments.  

Lifestyle changes, such as quitting smoking, exercising, and getting more calcium and vitamin D, can help prevent osteoporosis. For some breast cancer survivors, taking medications to treat osteoporosis and help prevent fractures is a good option. Speak with your healthcare provider to determine an individualized treatment plan that works for you.

A Word From Verywell

If you’ve just been diagnosed with breast cancer, osteoporosis is probably not in the forefront of your mind. Understandably, you’ll want to focus on your cancer treatment. 

But with more people now living for many years after their initial diagnosis, you’ll eventually want to consider your long-term health needs. Don’t hesitate to talk to your healthcare provider about getting assessed for osteoporosis and starting treatment if you need it.

Frequently Asked Questions

  • Does having breast cancer increase the risk that I’ll get osteoporosis?

    Yes, it can. Depending on the breast cancer treatment you receive, you may be at an increased risk for osteoporosis. However, other factors also affect your osteoporosis risk. Talk with your healthcare provider about the best ways to monitor your bone health and help prevent fractures.

  • Does having osteoporosis increase the risk that I’ll get breast cancer?

    No. Scientists have not discovered such a link.

11 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Choksi P, Williams M, Clark PM, et al. Skeletal manifestations of treatment of breast cancerCurr Osteoporos Rep. 2013;11(4):319-328. doi:10.1007/s11914-013-0179-7

  2. Ramin C, May BJ, Roden RBS, et al. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort studyBreast Cancer Res. 2018;20(1):134. doi:10.1186/s13058-018-1061-4

  3. Runowicz CD, Leach CR, Henry NL, et al. American cancer society/american society of clinical oncology breast cancer survivorship care guidelineCA Cancer J Clin. 2016;66(1):43-73. doi:10.3322/caac.21319

  4. Lee J, Alqudaihi HM, Kang MS, et al. Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study. Front Oncol. 2020;10:366. doi:10.3389/fonc.2020.00366

  5. Bailey S, Lin J. The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivorsBMC Womens Health. 2021;21(1):297. doi:10.1186/s12905-021-01430-1

  6. Ramchand SK, Cheung YM, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancerJ Endocrinol. 2019;241(3):R111-R124. doi:10.1530/JOE-19-0077

  7. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-2102. doi:10.1007/s00198-021-05900-y

  8. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment optionsP T. 2018;43(2):92-104.

  9. FDA label. Evista (raloxifene hydrochloride).

  10. Patel HK, Bihani T. Selective estrogen receptor modulators (serms) and selective estrogen receptor degraders (serds) in cancer treatmentPharmacol Ther. 2018;186:1-24. doi:10.1016/j.pharmthera.2017.12.012

  11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsLancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

By Ruth Jessen Hickman, MD
Ruth Jessen Hickman, MD, is a freelance medical and health writer and published book author.